Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Smallpox vaccine: problems and prospects.

Gregory A Poland1, John M Neff

  • 1Mayo Vaccine Research Group, Mayo Clinic and Foundation, 611C Guggenheim Building, 200 First Street SW, Rochester, MN 55905, USA. poland.gregory@mayo.edu

Immunology and Allergy Clinics of North America
|February 3, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vaccination policies for healthcare personnel in Europe, 2026.

Vaccine·2026
Same author

Vitamin A and body weight status do not impact humoral immunity against measles, mumps or rubella in individuals 4 to 18 years old: a cross-sectional cohort study in India.

Vaccine·2026
Same author

Cytomegalovirus serostatus and plasma MCP-1 levels are associated with antibody response to seasonal influenza vaccine across age and sex.

medRxiv : the preprint server for health sciences·2026
Same author

Sex-based differences in mumps immunity after a third dose of measles-mumps-rubella vaccine.

Vaccine·2026
Same author

Seroprevalence of mumps and rubella antibodies among Indian children: evidence of a mumps immunity gap.

Vaccine·2026
Same author

COVID-19 vaccine policy: a response and way forward.

Vaccine·2026
Same journal

Anaphylaxis: State-of-the-Art.

Immunology and allergy clinics of North America·2026
Same journal

Upending Impending Doom.

Immunology and allergy clinics of North America·2026
Same journal

Mast Cell Activation Syndrome and Mimickers.

Immunology and allergy clinics of North America·2026
Same journal

Hereditary Alpha-Tryptasemia (HαT) as a Risk Modifier for Severe Anaphylaxis.

Immunology and allergy clinics of North America·2026
Same journal

Emerging Therapies for Anaphylaxis.

Immunology and allergy clinics of North America·2026
Same journal

Novel Epinephrine Delivery Devices.

Immunology and allergy clinics of North America·2026
See all related articles

Newer smallpox vaccines are needed due to the risks of current live, attenuated vaccines. Research into safer subunit or peptide vaccines is crucial for widespread population protection against variola virus.

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Smallpox poses significant morbidity and mortality risks.
  • Current live, attenuated smallpox vaccines are highly reactogenic and have contraindications.
  • Widespread population susceptibility to smallpox necessitates effective countermeasures.

Purpose of the Study:

  • To highlight the need for safer and equally immunogenic smallpox vaccines.
  • To explore alternative vaccine platforms beyond live, attenuated viruses.
  • To identify research areas for predicting and preventing adverse vaccine reactions.

Main Methods:

  • Review of current smallpox vaccine technology and limitations.
  • Discussion of ongoing clinical trials for live, attenuated vaccines.

Related Experiment Videos

  • Exploration of subunit, peptide-based, and novel vaccine strategies.

    • Main Results:

    • Live, attenuated vaccines, while effective, carry risks of severe reactions.
    • Subunit or peptide-based vaccines offer potential safety advantages.
    • Understanding the mechanisms of adverse events like postvaccinal encephalitis is critical.

    Conclusions:

    • Development of safer, non-living smallpox vaccines is essential for universal preexposure vaccination.
    • Further research is needed to predict and prevent adverse reactions to existing and future vaccines.
    • Smallpox vaccines will likely remain a key public health tool, requiring ongoing innovation.